|
|
Isoherranen, Nina
- Assistant Professor
Selected Publications:
- Dickmann LJ, Tay S, Senn TD, Zhang H, Visone A, Unadkat JD, Hebert MF and Isoherranen N. "Changes in Maternal Liver CYP2C and CPY2D Expression and Activity During Rat Pregnancy" Biochemical Pharmacology 2008 in press.
- Hashizume T, Xu Y, Mohutsky MA, Alberts J, Hadden C, Kalhorn TF, Isoherranen N, Shuhart MC and Thummel KE. "Identification of Human UDP-Glucuronosyltransferases Catalyzing Hepatic 1alpha,25-dihydroxyvitamin D3 conjugation" Biochemical Pharmacology 2008 75:1240-1250.
- Isoherranen N, Givens RC, Ludington SS, Hawke RL, Pusek SN, Dees C, Blough D, Iwanaga K, Schuetz E, Watkins PB, Thummel KE and Paine MF. "Influence of CYP3A5 genotype on the extent of CYP3A inhibition in healthy African Americans" Drug Metab Dispos 2008 36:146-154.
- Templeton I, Kharasch E, Kunze KL, Hoffer C, Nelson W and Thummel KE and Isoherranen N. Role of itraconazole metabolites in CYP3A4 inhibition in vivo. Clin Pharmacol Ther 2007.
- Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel KE, Whittington D and Ensign D. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics and the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther 2007 82:410-426.
- Pearson JT, Hill JJ, Swain J, Isoherranen N, Kunze KL and Atkins WM. Surface plasmon Resonance analysis of antifungal azoles binding to CYP3A4 with kinetic resolution of multiple binding orietations. Biochemistry 2006 45:6341-6353.
- Dai Y, Hebert MF, Isoherranen
N, Davis CL, Marsh C, Shen DD, Thummel KE. Effect of CYP3A5
Polymorphism on Tacrolimus Metabolic Clearance In Vitro. Drug Metab
Dispos. 2006 May;34(5):836-47
- Kunze KL, Nelson WL, Kharasch
ED, Thummel KE, Isoherranen N. Stereochemical aspects
of itraconazole metabolism in vitro and in vivo. Drug Metab Dispos.
2006 Apr;34(4):583-90. Epub 2006 Jan 13.
- Huang W, Lin YS, McConn
D, Calamia JC, Totah RH, Isoherranen N, Glowdowski
M and Thummel KE. Evidence of Significant Contribution from CYP3A5
to Hepatic Drug Metabolism. Drug Metab. Dispos. 32:1434-1445,
2004.
- Isoherranen N,
Kunze KL, Allen KE, Nelson WL and Thummel KE. Role of itraconazole
metabolites in CYP3A4 inhibition. Drug Metab. Dispos.
32 :1121-1131, 2004.
- Isoherranen N,
Levy RH, Yagen B, Woodhead JH, White HS and Bialer M. Metabolism
of a new antiepileptic drug N-methyl- tetramethylcyclopropane
carboxamide and anticonvulsant activity of its metabolites. Epilepsy
Res 58: 1-12, 2004.
- Isoherranen N,
Spiegelstein O, Bialer M, Zhang J, Merriweather M, Yagen B, Roeder
M, Tripplett A, Schurig V and Finnell RH. Developmental outcome
of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric
acid, and its enantiomer (R)- a -ethyl-oxo-pyrrolidine acetate in a
mouse model of teratogenicity. Epilepsia 44: 1280-1288,
2003.
- Isoherranen N,
Yagen B, Spiegelstein O, Finnell RH, Merriweather M, Woodhead
JH, Wlodarczyk B, White HS and Bialer M. Anticonvulsant Activity,
teratogenicity and pharmacokinetics of novel valproyltaurine derivatives.
Brit J. Pharmacol. 139 :755-764, 2003.
- Britzi M, Soback S, Isoherranen
N, Levy RH, Perucca E, Doose DR, Maryanoff B and Bialer
M. Analysis of Topiramate and its Metabolites in Plasma and Urine of
Healthy Subjects and Patients With Epilepsy by Use of a Novel Liquid
Chromatography-Mass Spectrometry assay. Ther. Drug Monit. 25:
314-322, 2003.
- Isoherranen N,
White HS, Klein BD, Roeder M, Woodhead JH, Schurig V, Yagen B
and Bialer M. Pharmacokinetic-Pharmacodynamic relationships of
(2S,3S)-Valnoctamide and its stereoisomer (2R,3S)-Valnoctamide in rodent
models of epilepsy. Pharm Res 20: 1293-1301, 2003.
- Isoherranen
N, Yagen B and Bialer M. New antiepileptic and CNS
drugs that are second generation valproic acid. Can they lead to the
development of a magic bullet? Curr. Opin. Neurol. 16:
203-211, 2003.
- Isoherranen
N, Yagen B, Woodhead JH, Spiegelstein O, Blotnik S, Wilcox
KS, Finnell RH, Bennett GD, White HS and Bialer M. Characterization
of the anticonvulsant activity and Pharmacokinetics of Propylisopropyl
acetamide and its enantiomers in rodents. Brit J. Pharmacol .
138: 602-613, 2003.
- Isoherranen
N, White HS, Finnell RH, Woodhead JH, Yagen B, Bennett
GD, Wilcox KE, Barton ME and Bialer M. Anticonvulsant
Activity and Teratogenicity of N-methyl tetramethylcyclopropyl carboxamide.
Epilepsia 43:115-126, 2002.
- Isoherranen
N, Woodhead JH, White HS and Bialer M. Anticonvulsant
profile of valproyl glycinamide (TV1901): A new antiepileptic and CNS
drug. Epilepsia 42: 831-836, 2001.
- Isoherranen
N, Yagen B, Roeder M, Soback S, Schurig V and Bialer M.
Pharmacokinetics of levetiracetam and its enantiomer (R)- a -ethyl-oxo-pyrrolidine
acetamide in dogs. Epilepsia 42: 825-830, 2001.
- Isoherranen
N and Soback S. Determination of gentamicin after trimethylsilylimidazole
and trifluoroacetic anhydride derivatization using gas chromatography
and negative ion chemical ionization ion trap mass spectrometry. Analyst 125: 1573-1576, 2000.
- Isoherranen
N, Lavi E and Soback S. Pharmacokinetics of Gentamicin
C 1 , C 1a , and C 2 in Beagles after a Single Intravenous Dose. Antimicrob.
Agents Chemother 44 :1443-1447, 2000.
|
